Literature DB >> 17630961

T-box factors: targeting to chromatin and interaction with the histone H3 N-terminal tail.

Florence Demay1, Bilada Bilican, Mercedes Rodriguez, Suzanne Carreira, Marco Pontecorvi, Yan Ling, Colin R Goding.   

Abstract

T-box transcription factors play a crucial role in development where they are implicated in patterning and cell fate decisions. Tbx2 and Tbx3 have also been implicated in several cancers including melanoma, and can act as antisenescence factors through their ability to repress p19(ARF) and p21(CIP1) expression. Although several target genes for T-box factors have been identified, it is unknown whether this family of proteins can bind chromatin, a property that would facilitate the epigenetic reprogramming that occurs in both development and cancer progression. Here, we show that Tbx2 has the potential to recognize mitotic chromatin in a DNA-dependent fashion, can interact specifically with the histone H3 N-terminal tail, a property shared with Tbx4, Tbx5 and Tbx6, and can also recognize nucleosomal DNA, with binding to nucleosomes being antagonized by the presence of the histone tails. Strikingly, in vivo Tbx2 co-localization with pericentric heterochromatin appears to be regulated and ectopic expression of Tbx2 leads to severe mitotic defects. Taken together our results suggest that Tbx2, and most likely other members of the T-box family, are able to target chromatin and may indicate a role for the T-box factors in epigenetic reprogramming events.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17630961     DOI: 10.1111/j.1600-0749.2007.00389.x

Source DB:  PubMed          Journal:  Pigment Cell Res        ISSN: 0893-5785


  12 in total

Review 1.  Molecular pathology of cutaneous melanoma.

Authors:  Léon C van Kempen; Margaret Redpath; Caroline Robert; Alan Spatz
Journal:  Melanoma Manag       Date:  2014-12-04

2.  TBX2 expression is associated with platinum-sensitivity of ovarian serous carcinoma.

Authors:  Reiko Tasaka; Takeshi Fukuda; Masahiro Shimomura; Yuta Inoue; Takuma Wada; Masaru Kawanishi; Tomoyo Yasui; Toshiyuki Sumi
Journal:  Oncol Lett       Date:  2017-12-29       Impact factor: 2.967

3.  The retinoblastoma protein modulates Tbx2 functional specificity.

Authors:  Keith W Vance; Heather M Shaw; Mercedes Rodriguez; Sascha Ott; Colin R Goding
Journal:  Mol Biol Cell       Date:  2010-06-09       Impact factor: 4.138

4.  TBX3 regulates splicing in vivo: a novel molecular mechanism for Ulnar-mammary syndrome.

Authors:  Pavan Kumar P; Sarah Franklin; Uchenna Emechebe; Hao Hu; Barry Moore; Chris Lehman; Mark Yandell; Anne M Moon
Journal:  PLoS Genet       Date:  2014-03-27       Impact factor: 5.917

5.  The orthologous Tbx transcription factors Omb and TBX2 induce epithelial cell migration and extrusion in vivo without involvement of matrix metalloproteinases.

Authors:  Jie Shen; Juan Lu; Liyuan Sui; Dan Wang; Meizhen Yin; Inka Hoffmann; Anne Legler; Gert O Pflugfelder
Journal:  Oncotarget       Date:  2014-12-15

6.  Putative Breast Cancer Driver Mutations in TBX3 Cause Impaired Transcriptional Repression.

Authors:  Kathrin Fischer; Gert O Pflugfelder
Journal:  Front Oncol       Date:  2015-10-29       Impact factor: 6.244

7.  Novel HDAC5-interacting motifs of Tbx3 are essential for the suppression of E-cadherin expression and for the promotion of metastasis in hepatocellular carcinoma.

Authors:  Liang Dong; Qi Dong; Ying Chen; Yichen Li; Bao Zhang; Fanghang Zhou; Xiaoming Lyu; George G Chen; Paul Lai; Hsiang-Fu Kung; Ming-Liang He
Journal:  Signal Transduct Target Ther       Date:  2018-08-24

8.  Transcriptomic Alterations in Lung Adenocarcinoma Unveil New Mechanisms Targeted by the TBX2 Subfamily of Tumor Suppressor Genes.

Authors:  Athar Khalil; Batoul Dekmak; Fouad Boulos; Jake Kantrowitz; Avrum Spira; Junya Fujimoto; Humam Kadara; Nehme El-Hachem; Georges Nemer
Journal:  Front Oncol       Date:  2018-10-30       Impact factor: 6.244

9.  Tbx3 represses PTEN and is over-expressed in head and neck squamous cell carcinoma.

Authors:  Durmus Burgucu; Kenan Guney; Duygu Sahinturk; Irem Hicran Ozbudak; Deniz Ozel; Gulay Ozbilim; Ugur Yavuzer
Journal:  BMC Cancer       Date:  2012-10-19       Impact factor: 4.430

10.  TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.

Authors:  Zenobia C D'Costa; Catherine Higgins; Chee Wee Ong; Gareth W Irwin; David Boyle; Darragh G McArt; Karen McCloskey; Niamh E Buckley; Nyree T Crawford; Lalitha Thiagarajan; James T Murray; Richard D Kennedy; Karl A Mulligan; D Paul Harkin; David J J Waugh; Chris J Scott; Manuel Salto-Tellez; Richard Williams; Paul B Mullan
Journal:  Oncotarget       Date:  2014-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.